Progenics Pharmaceuticals Inc. (PGNX) stock prices updated...
 

Progenics Pharmaceuticals Inc. stock price

Progenics Pharmaceuticals Inc. latest news:


  • 12/29/2017 06:40:08

    Progenics shares jump 21% premarket after FDA says it will review treatment for rare cancer

    Shares of Progenics Pharmaceuticals Inc. surged 21% in premarket trade Friday, after the company said the U.S. Food and Drug Administration has accepted for review its new drug application for Azedra in patients with rare neuroendocrine tumors. "With no FDA-approved therapies for these rare tumors, AZEDRA has the potential to address the high unmet need of patients with malignant pheochromocytoma and paraganglioma," Chief Executive Mark Baker said in a statement. The NDA is based on data from a mid-stage trial that met its primary and secondary endpoints, said the company. Progrenics shares are down 32% in 2017 through Thursday, while the S&P 500 has gained 20%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Progress Software CorporationPRGS | ProNAi Therapeutics, Inc.DNAI | Proofpoint, Inc.PFPT | ProPhase Labs, Inc.PRPH | ProQR Therapeutics N.V.PRQR | ProShares Ultra search BiotechnologyBIB | Proshares UltraPro search BiotechnologyUBIO | ProShares UltraPro QQQTQQQ | ProShares UltraPro Short search BiotechnologyZBIO | ProShares UltraPro Short QQQSQQQ |